Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can we predict who will worsen? new study analyzes 2000 PE patients

NCT ID NCT05481242

Knowledge-focused Sponsor: Shengjing Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked back at medical records from 2000 adults hospitalized with a blood clot in the lungs (pulmonary embolism). Researchers collected lab tests and CT scan results to see which patients later had serious problems like death, needing a breathing machine, or emergency treatment within 30 days. The goal is to find better ways to predict who is at highest risk for worsening.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2011

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Chinese

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age of ≥ 18 years and a pulmonary embolism diagnosis based on CT pulmonary angiography Exclusion Criteria: * pregnancy * reception of reperfusion treatment before admission * missing data regarding CT parameters, echocardiography, cardiac troponin I (c-Tn I), and N-terminal-pro brain natriuretic peptide (NT-pro BNP) levels.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Deterioration, clinical are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Clinical Deterioration pulmonary embolism thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Deterioration, clinical Pulmonary embolism and thrombosis

Contacts and locations

Locations

  • Shenjing Hospital of CHINA MEDICAL UNIVERSITY

    Shenyang, Liaoning, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.